Compare Moody's Corporation (MCO) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moody's Corporation vs Recursion Pharmaceuticals Inc — how do they compare? Moody's Corporation trades at $460 (market cap $77.87B), while Recursion Pharmaceuticals Inc trades at $4.01 (market cap $2.31B). The key difference: Moody's Corporation is far larger — about 33.7× Recursion Pharmaceuticals Inc's market cap, and Moody's Corporation pays a 0.92% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Moody's Corporation for 132 Days and Recursion Pharmaceuticals Inc for 22 Days on average.
| MCO | RXRX | |
|---|---|---|
Market Cap | $77.87B | $2.31B |
Volume | 633,412 | 40,478,768 |
Sector | Financials | Health |
52-Week High | $539.61 | $6.79 |
52-Week Low | $412.23 | $2.84 |
Typical Hold Time | 132 Days | 22 Days |
Enterprise Value | $83.89B | $1.83B |
Dividend Yield | 0.92% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moody's Corporation (MCO) trades at $458.69, up 1.41% with strong fundamentals including 34.25% net income margin and 80.15% ROE. The stock shows bearish technical signals but has consistently beaten earnings estimates in recent quarters. Recent developments include a minority stake acquisition in Philippine Rating Services and continued leadership in risk analytics, with the company ranking #1 in Chartis RiskTech100 for the fifth consecutive year.
Despite technical weakness, Moody's maintains strong profitability and analyst support with 56% buy ratings and a $536.40 consensus target. Key risks include high valuation multiples and potential market volatility, but the company's dominant market position and consistent earnings growth support long-term investment appeal.
RXRX trades at $4.27, down 7.78% today, with a bullish technical signal from moving averages but negative profitability. The company reported a net loss of -$644.76M in 2025, with revenue of $74.26M, and has beaten earnings estimates in two of the last three quarters. Recent news highlights strategic AI partnerships and pipeline expansion, though financial performance remains challenged.
The outlook is mixed: analyst consensus is 40% buy, 60% hold, with no sell ratings, indicating cautious optimism for long-term AI-driven growth. Key risks include persistent cash burn, high valuation multiples, and slow revenue growth. Upside depends on successful drug development and partnership milestones, but near-term profitability remains elusive.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Moody's Corporation
Moody's, along with S&P Ratings, is a leading provider of credit ratings on fixed income securities. Moody's ratings segment, known as Moody's Investors Service or MIS, includes corporates, structured finance, financial institutions, and public finance ratings. MIS represents a majority of the firm's revenue and profits. Moody's other segment is Moody's Analytics and consists of Research, Data, and Analytics or RD&A and Enterprise Risk Solutions or ERS. RD&A's products include credit research, quantitative credit scores, economic research, business intelligence, know your customer (KYC) tools, commercial real estate data and analytical tools, and training services. ERS includes risk management software solutions to financial institutions.
Read more on MCO →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
